Abstract
Recent data from a national survey highlighted a significant difference in obesity rates in young fragile X males (31%) compared to age matched controls (18%). Fragile X syndrome (FXS) is the most common cause of intellectual disability in males and the most common single gene cause of autism. This X-linked disorder is caused by an expansion of a trinucleotide CGG repeat ( > 200) on the promotor region of the fragile X mental retardation 1 gene (FMR1). As a result, the promotor region often becomes methylated which leads to a deficiency or absence of the FMR1 protein (FMRP). Common characteristics of FXS include mild to severe cognitive impairments in males but less severe cognitive impairment in females. Physical features of FXS include an elongated face, prominent ears, and post-pubertal macroorchidism. Severe obesity in full mutation males is often associated with the Prader-Willi phenotype (PWP) which includes hyperphagia, lack of satiation after meals, and hypogonadism or delayed puberty; however, there is no deletion at 15q11-q13 nor uniparental maternal disomy. Herein, we discuss the molecular mechanisms leading to FXS and the Prader-Willi phenotype with an emphasis on mouse FMR1 knockout studies that have shown the reversal of weight increase through mGluR antagonists. Finally, we review the current medications used in treatment of FXS including the atypical antipsychotics that can lead to weight gain and the research regarding the use of targeted treatments in FXS that will hopefully have a significantly beneficial effect on cognition and behavior without weight gain.
Keywords: Fragile X, trinucleotide repeat, Prader-Willi phenotype, obesity, mGluR antagonists, GABA, intellectual disability, autism, cognitive impairments, post-pubertal macroorchidism
Current Genomics
Title: Fragile X Syndrome
Volume: 12 Issue: 3
Author(s): Yingratana McLennan, Jonathan Polussa, Flora Tassone and Randi Hagerman
Affiliation:
Keywords: Fragile X, trinucleotide repeat, Prader-Willi phenotype, obesity, mGluR antagonists, GABA, intellectual disability, autism, cognitive impairments, post-pubertal macroorchidism
Abstract: Recent data from a national survey highlighted a significant difference in obesity rates in young fragile X males (31%) compared to age matched controls (18%). Fragile X syndrome (FXS) is the most common cause of intellectual disability in males and the most common single gene cause of autism. This X-linked disorder is caused by an expansion of a trinucleotide CGG repeat ( > 200) on the promotor region of the fragile X mental retardation 1 gene (FMR1). As a result, the promotor region often becomes methylated which leads to a deficiency or absence of the FMR1 protein (FMRP). Common characteristics of FXS include mild to severe cognitive impairments in males but less severe cognitive impairment in females. Physical features of FXS include an elongated face, prominent ears, and post-pubertal macroorchidism. Severe obesity in full mutation males is often associated with the Prader-Willi phenotype (PWP) which includes hyperphagia, lack of satiation after meals, and hypogonadism or delayed puberty; however, there is no deletion at 15q11-q13 nor uniparental maternal disomy. Herein, we discuss the molecular mechanisms leading to FXS and the Prader-Willi phenotype with an emphasis on mouse FMR1 knockout studies that have shown the reversal of weight increase through mGluR antagonists. Finally, we review the current medications used in treatment of FXS including the atypical antipsychotics that can lead to weight gain and the research regarding the use of targeted treatments in FXS that will hopefully have a significantly beneficial effect on cognition and behavior without weight gain.
Export Options
About this article
Cite this article as:
McLennan Yingratana, Polussa Jonathan, Tassone Flora and Hagerman Randi, Fragile X Syndrome, Current Genomics 2011; 12 (3) . https://dx.doi.org/10.2174/138920211795677886
DOI https://dx.doi.org/10.2174/138920211795677886 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry Clozapine Safety, 40 Years Later
Current Drug Safety Genetics of Obesity: What have we Learned?
Current Genomics Predicting Factors of Worse Prognosis in COVID-19: Results from a Cross-sectional Study on 52 Inpatients Admitted to the Internal Medicine Department
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Therapeutic Targets for the Treatment of Depression
Current Medicinal Chemistry - Central Nervous System Agents Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases
Current Topics in Medicinal Chemistry Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Cannabinoids for the Treatment of Schizophrenia: An Overview
Current Topics in Medicinal Chemistry Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Kisspeptins, Estrogens and Male Fertility
Current Medicinal Chemistry On the Role of Neuropeptides in the Hypothalamic Regulation of Food Intake
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Oligomerization of G Protein-Coupled Receptors: Biochemical and Biophysical Methods
Current Medicinal Chemistry Adrenomedullin in Hypertension
Current Hypertension Reviews